natgillin/translations-raw huggingface dataset:
The incidence rates for moderate and severe pain after Optaflu vaccination are similar to those of egg-derived influenza vaccines; however a slightly increased risk for mild short-lasting injection site pain was observed with Optaflu in the subgroup of elderly vaccinees (8% compared to 6% with egg-derived influenza vaccine).
Stopnja pogostnosti zmerne in hude bolečine po cepljenju s cepivom Optaflu je podobna stopnji pri cepivih, pridobljenih iz jajc; vendar so pri cepivu Optaflu opazili rahlo povečano tveganje za pojav blage kratkotrajne bolečine na mestu injiciranja v podskupini starejših oseb, ki so jih cepili (8 % v primerjavi s 6 % pri cepivu, pridobljenem iz jajc).
The vaccine should be allowed to reach room temperature before use.
Cepivo se mora pred uporabo ogreti na sobno temperaturo.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Optaflu (2015/2016 season)
IME ZDRAVILA IN POT(I) UPORABE Optaflu (sezona 2015/2016)
Not known (cannot be estimated from the available data) Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
neznana (ni mogoče oceniti iz razpoložljivih podatkov) V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
In this comparative trial against an egg-derived influenza vaccine the seroprotection* rate, seroconversion or significant increase rate** and the geometric mean ratio (GMR) for anti-HA antibody (measured by HI) were assessed according to predefined criteria.
V tem primerjalnem preskušanju s cepivom, pridobljenim iz jajc, so bili stopnja serološke zaščite*, stopnja serološke konverzije ali pomembnega povečanja** in razmerje geometrične srednje vrednosti (GMR - Geometric Mean Ratio) za protitelesa proti HA (izmerjeno z inhibicijo hemaglutinina) ocenjeni glede na predhodno določene kriterije.
• your doctor or nurse will make sure that appropriate medical treatment and supervision is readily available in case of a rare anaphylactic reaction (a very severe allergic reaction with symptoms such as difficulty in breathing, dizziness, a weak and rapid pulse and skin rash) following the administration.
• bosta zdravnik ali medicinska sestra zagotovila, da bosta na voljo ustrezno zdravljenje in zdravstveni nadzor v primeru redke anafilaktične reakcije (zelo hude alergijske reakcije s simptomi, kot so težave pri dihanju, vrtoglavica, šibek in hiter srčni utrip ter kožni izpuščaj) po uporabi.
% Lower Limit of One-Sided 97.5% CI
% Spodnja meja enostranskega 97,5-% IZ
Healthcare professionols are asked to report any suspected adverse reactions via the national reporting sytem listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
What Optaflu is and what it is used for What you need to know before you receive Optaflu
Kaj je cepivo Optaflu in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo Optaflu
Influenza cases were identified by active and passive surveillance of influenza-like illness (ILI).
Primeri gripe so bili odkriti z aktivnim in pasivnim spremljanjem gripi podobnih bolezni (ILI - influenza-like illness).
ILI was defined according to Centers for Disease Control and Prevention (CDC) case definition, i.e., a fever (oral temperature ≥ 100.0°F / 38°C) and cough or sore throat.
ILI so opredelili v skladu z opredelitvijo primera Centra za nadzor in preprečevanje bolezni (Centers for Disease Control and Prevention (CDC)), tj. zvišana telesna temperatura (oralna temperatura ≥38 °C) in kašelj ali boleče žrelo.
Optaflu may be given at the same time as other vaccines.
Cepivo Optaflu se lahko daje sočasno z drugimi cepivi.
• if you have an acute illness associated with fever.
• če imate akutno bolezen, ki jo spremlja povišana telesna temperatura.
Across all three influenza strains, for the egg-derived vaccine seroprotection rates ranged between 85% and 98%, seroconversion or significant increase rates ranged between 62% and 73% and GMRs ranged between 5.52- and 8.76-fold over baseline HI titers.
Pri vseh treh sevih gripe je bila stopnja serološke zaščite pri cepivih, pridobljenih iz jajc, med 85 in 98 %, stopnja serološke konverzije ali pomembnega povečanja je bila med 62 in 73 %, razmerje geometrične srednje vrednosti pa je bilo od 5,52- do 8,76-kratno v primerjavi z izhodiščnimi titri HI.
Outer carton box will include “Blue Box”.
Zunanja kartonska škatla vključuje podatke za tako imenovano »modro okence«.
This reaction may occur with Optaflu as with all vaccines that are injected.
Do te reakcije lahko pride pri uporabi cepiva Optaflu tako kot pri vseh cepivih, ki se injicirajo;
- Neurological disorders, such as Guillain Barré syndrome, encephalomyelitis and neuritis
- Nevrološke motnje, kot so GuillainBarréjev sindrom, encefalomielit is in nevritis
Immunisation should be carried out by intramuscular injection into the deltoid muscle.
Imunizacijo je treba opraviti z intramuskularnim injiciranjem v deltoidno mišico.
Prophylaxis of influenza for adults, especially in those who run an increased risk of associated
Profilaksa gripe pri odraslih, zlasti pri tistih, pri katerih obstaja večje tveganje za zaplete, povezane
Optaflu has not been studied in the paediatric population and therefore, data on immune response are not available for this age group.
Cepiva Optaflu pri pediatrični populaciji niso raziskovali, zato podatki o imunskem odzivu pri tej
A/Switzerland/9715293/2013 (H3N2) - like strain
Sevu A/Switzerland/9715293/2013 (H3N2) podoben sev
Neuralgia, convulsion, febrile convulsion.
Nevralgija, konvulzija, febrilna konvulzija.
The following side effects have been observed during clinical trials and post-marketing surveillance:
Naslednje neželene učinke so opazili med kliničnimi preskušanji in v obdobju po začetku trženja:
No differences were observed between the cell-culture and the comparator egg-derived vaccine.
Razlik med celično kulturo in primerjalnim cepivom, pridobljenim iz jajc, niso opazili.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET
- Vasculitis, possibly associated with transient renal involvement
- Vaskulitis, ki je lahko povezan s prehodno prizadetostjo ledvic
Vaccine Efficacy = (1 - Relative Risk) x 100 %; ** There were too few cases of influenza due to vaccine-matched influenza A/H3N2 or B to adequately assess vaccine efficacy.
Učinkovitost cepiva = (1 - relativno tveganje) x 100 %; ** Primerov gripe, ki bi se ujemali s cepilnima sevoma virusa gripe A/H3N2 in B, je bilo premalo za
OTHER SPECIAL WARNING(S), IF NECESSARY Do not inject intravascularly.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Ne injicirajte intravaskularno.
Tell your doctor if you are pregnant, think you may be pregnant or plan to become pregnant.
Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom.
Tell the doctor requesting the test that you have recently received Optaflu.
Zdravniku, ki je teste naročil, povejte, da ste se pred kratkim cepili s cepivom Optaflu.
Table 2: Vaccine Efficacy against Culture-Confirmed Influenza Attack Rate (%)
Preglednica 2: Učinkovitost cepiva proti laboratorijsko potrjeni gripi z gripo Pojavnost (%)
** Seroconversion = negative pre-vaccination HI titer and post-vaccination HI titer ≥40; significant increase = positive pre-vaccination HI titer and at least a 4-fold increase in post-vaccination HI titer.
** Serološka konverzija = negativni titer HI pred cepljenjem in titer po cepljenju ≥ 40; pomembno povečanje = pozitiven titer HI pred cepljenjem in vsaj 4-kratno povečanje titra HI po cepljenju.
Efficacy against Culture-Confirmed Influenza
Učinkovitost proti laboratorijsko potrjeni gripi
Vaccine Efficacy* % Lower Limit of OneSided 97.5% CI
Učinkovitost cepiva* % Spodnja meja enostranskega 97,5-% IZ
A/California/7/2009 (H1N1)pdm09 - like strain
Sevu A/California/7/2009 (H1N1)pdm09 podoben sev
Optaflu may have a minor effect on your ability to drive and use machines.
Cepivo Optaflu ima lahko majhen vpliv na vašo sposobnost vožnje in upravljanja strojev.
Tell your doctor immediately or go to the casualty department at your nearest hospital if you experience the following side effect - you may need urgent medical attention or hospitalisation:
Takoj povejte zdravniku ali pojdite v ambulanto za nujne primere v najbližjo bolnišnico, če opazite naslednje neželene učinke; morda boste potrebovali nujno medicinsko pomoč ali se boste morali
Due to the kind of manufacturing Optaflu is free of When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection against the influenza virus.
Ko je oseba cepljena, bo imunski sistem (naravni obrambni sistem telesa) začel proizvajati lastno zaščito proti virusu gripe.
Ask you pharmacist how to throw away medicines you no longer use.
O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
Therefore, Optaflu is not recommended for use in children and adolescents less than 18 years of age (see section 5.1).
Uporaba cepiva Optaflu pri otrocih in mladostnikih, starih do 18 let, zato ni priporočljiva (glejte poglavje 5.1).
Optaflu is available in packs containing 1 or 10 pre-filled syringes and in multipacks comprising 2 cartons, each containing 10 pre-filled syringes.
Cepivo Optaflu je na voljo v pakiranjih z 1 ali 10 napolnjenimi injekcijskimi brizgami in v večkratnih pakiranjih z 2 škatlama, od katerih vsaka vsebuje po 10 napolnjenih injekcijskih brizg.
• difficulty in breathing, dizziness, a weak and rapid pulse and skin rash which are symptoms of an anaphylactic reaction (a very severe allergic reaction)
• težave pri dihanju, vrtoglavica, šibek in hiter srčni utrip ter kožni izpuščaj, ki so simptomi anafilaktičnega reakcije (zelo hude alergijske reakcije).
The use of this vaccine may be considered from the second trimester of pregnancy.
O možnosti uporabe cepiva se lahko odloča od drugega trimesečja nosečnosti naprej.
Do not use this vaccine after the expiry date which is stated on the label and carton after EXP.
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP. Rok uporabnosti cepiva se izteče na zadnji dan navedenega meseca.
This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially ‘potassium-free'.
To cepivo vsebuje manj kot 1 mmol (39 mg) kalija na odmerek, kar v bistvu pomeni ‘brez kalija'.
• painful disorders of the nerves, e.g. attacks of extreme pain in the face, throat or ear fits
• boleče motnje živcev, npr. napadi hude bolečine v obrazu, grlu ali ušesu; epileptični napadi
Suspension for injection in pre-filled syringe.
Suspenzija za injiciranje v napolnjeni injekcijski brizgi.
Immunisation shall be postponed in patients with febrile illness or acute infection.
Pri bolnikih s febrilno boleznijo ali akutno okužbo je treba imunizacijo preložiti.
Optaflu contains sodium chloride and potassium chloride This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
Cepivo Optaflu vsebuje natrijev klorid in kalijev klorid To cepivo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni ‘brez natrija'.
Your doctor will decide if you should receive Optaflu.
Vaš zdravnik se bo odločil, ali boste cepljeni s cepivom Optaflu.
This includes any possible side effects not listed in this leaflet.You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
The use of Optaflu may be considered from the second trimester of pregnancy.
Možnost uporabe cepiva Optaflu se lahko pretehta od drugega trimesečja nosečnosti naprej.
Justification for not using Braille accepted.
Sprejeta je utemeljitev, da Braillova pisava ni potrebna
* Simultaneous one-sided 97.5% confidence intervals for the vaccine efficacy of each influenza vaccine relative to placebo based on the Sidak-corrected score confidence intervals for the two relative risks.
* Sočasni enostranski 97,5-odstotni intervali zaupanja za učinkovitost cepljenja s cepivi proti gripi glede na placebo, ki temeljijo na Šidakovih intervalih zaupanja s korekcijo točk za obe vrednosti relativnega tveganja.
Optaflu is not recommended for use in children below 18 years of age since there is no information available.
Otroci in mladostniki: Uporabe cepiva Optaflu se ne priporoča za otroke, stare manj kot 18 let, saj podatki niso na voljo.
Male fertility has not been assessed in animals (see section 5.3).
Plodnost samcev na živalih ni bila ocenjena (glejte poglavje 5.3).
• flu-like symptoms such as headache, feeling of discomfort, tiredness, muscle pain.
• simptomi, podobni gripi, kot so glavobol, občutek nelagodja, utrujenost, bolečine v mišicah.
Optaflu may be used during breast feeding.
Cepivo Optaflu se lahko uporablja med dojenjem.
* propagated in Madin Darby Canine Kidney (MDCK) cells
* razmnoženi v celicah pasjih ledvic Madin Darby (MDCK)
Animal studies do not indicate reproductive toxicity (see Section 5.3 - Preclinical safety data).
Študije na živalih ne kažejo vplivov na sposobnost razmnoževanja (glejte poglavje 5.3 - Predklinični podatki o varnosti).
In general data from influenza vaccinations in pregnant women do not indicate adverse foetal and maternal outcomes attributable to the vaccine.
Podatki iz cepljenj proti gripi pri nosečnicah na splošno ne kažejo na neželene učinke na plod ali mater, ki bi jih lahko pripisali cepivu.
Very Rare (affects less than 1 user in 10,000): • bleeding or bruising which are symptoms of a low platelet count in the blood
Zelo redki (pojavijo se pri manj kot 1 od 10.000 cepljenih): • krvavitve ali modrice, ki so simptomi majhnega števila trombocitov v krvi.
The PSUR cycle for the medicinal product should follow a twice-yearly cycle until otherwise agreed
• Redno posodobljena poročila o varnosti zdravila (PSUR) Cikel PSUR za zdravilo mora slediti polletnemu ciklu dokler CHMP ne odloči drugače.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Neuporabljeno cepivo in drug odpadni material zavrzite v skladu z lokalnimi predpisi za
• Fainting can occur following, or even before, any needle injection.
• po katerem koli injiciranju z iglo ali celo pred njim se lahko pojavi omedlevica.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING MULTIPACK - Inner Carton Box for 10 pre-filled syringes with needles - Inner Carton Box for 10 pre-filled syringes without needles Inner carton box will not include “Blue Box”.
VEČKRATNO PAKIRANJE - Notranja kartonska škatla za 10 napolnjenih injekcijskih brizg z iglami - Notranja kartonska škatla za 10 napolnjenih injekcijskih brizg brez igel Notranja kartonska škatla ne vključuje podatke za tako imenovano »modro okence«.
Uncommon (affects 1 to 10 users in 1,000): • generalised skin reactions such as itching, bumps on the skin or non-specific rash
Občasni (pojavijo se pri 1 do 10 od 1.000 cepljenih): • splošne kožne reakcije, kot so srbenje, bule na koži ali neznačilni izpuščaj.
Note that the side effects of the vaccines may be intensified.
Neželeni učinki cepiv so lahko okrepljeni.
Detailed information on this medicinal product is available on the website of the European Medicines
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila
For pregnant women with medical conditions that increase their risk of complications from influenza, administration of the vaccine is recommended, irrespective of their stage of pregnancy.
Za nosečnice z boleznimi, ki povečujejo tveganje za pojav zapletov pri gripi, je uporaba cepiva proti gripi priporočena, ne glede na fazo nosečnosti.
0.5 ml suspension in pre-filled syringes (type I glass), with a plunger stopper (bromobutyl rubber).
0,5 ml suspenzije v napolnjenih injekcijskih brizgah (steklo vrste I) z batnim zamaškom iz bromobutilne gume.
4.8 Undesirable effects a) Summary of safety profile
4.8 Neželeni učinki
Optaflu is injected into the muscle on the top of the upper arm (deltoid muscle).
Cepivo Optaflu se injicira v mišico na vrhu nadlakti (deltoidna mišica).
Injection site pain and headache were common in the elderly.
Pri starejših sta bila bolečina na mestu injiciranja in glavobol pogosta.
15 micrograms HA** 15 micrograms HA** per 0.5 ml dose
15 mikrogramov HA** 15 mikrogramov HA** na 0,5-mililitrski odmerek
The persistence of postvaccination antibodies to strains included in the vaccine is usually 6-12 months, as shown by studies performed during the clinical development of this vaccine.
Kot so pokazale študije, opravljene pri kliničnem razvoju tega cepiva, obstojnost protiteles proti sevom, vključenim v cepivo, po cepljenju navadno traja 6 do 12 mesecev.
Safety and reactogenicity evaluations were performed for all subjects during the first 3 weeks following vaccination and SAEs have been collected for approximately 6700 vaccinees during six
Pri vseh osebah v prvih treh tednih po cepljenju ter pri približno 6700 cepljenih osebah med šestmesečnim obdobjem sledenja so ocenili varnost in reaktogenost ter zbrali podatke o resnih
The other ingredients are: sodium chloride, potassium chloride, magnesium chloride hexahydrate, disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections.
Druge sestavine cepiva so: natrijev klorid, kalijev klorid, magnezijev klorid heksahidrat, natrijev hidrogenfosfat dihidrat, kalijev dihidrogenfosfat in voda za injekcije.
The expiry date refers to the last day of that month.
Navodilo je bilo nazadnje revidirano dne.
INFORMATION IN BRAILLE Justification for not using Braille accepted.
PODATKI V BRAILLOVI PISAVI Sprejeta je utemeljitev, da Braillova pisava ni potrebna
Optaflu should under no circumstances be administered intravascularly.
Cepivo Optaflu se pod nobenim pogojem ne sme dajati intravaskularno.
Uncommon ≥ 1/1000 to
Občasni ≥ 1/1.000 do
Optaflu is a clear to slightly opalescent suspension.
Cepivo Optaflu je bistra do rahlo motna suspenzija.
After an episode of ILI, nose and throat swab samples were collected for analysis.
Po epizodi ILI so za preiskavo odvzeli brise nosu in žrela.
Animal data have not shown effects on female fertility (see section 5.3).
Podatki, pridobljeni na živalih, ne kažejo vplivov na plodnost samic (glejte poglavje 5.3).
• fever, headache, vomiting and drowsiness progressing to coma or fits (convulsions) which are symptoms of an inflammation of the brain and spinal cord
• zvišana telesna temperatura, glavobol, bruhanje in dremavost, ki se stopnjuje v komo ali epileptične napade (konvulzije), ki so simptomi vnetja možganov in hrbtenjače
Tell your doctor or nurse if you are using, have recently used or might use any other medicines, including medicines obtained without a prescription or if you have recently received any other
Obvestite zdravnika ali medicinsko sestro, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection.
Po katerem koli cepljenju ali celo pred njim, se lahko kot psihogeni odziv na injiciranje z iglo, pojavi sinkopa (omedlevica).
Optaflu is given to you by your doctor or nurse.
Cepivo Optaflu vam da zdravnik ali medicinska sestra.
15 micrograms HA** per 0.5 ml dose
15 mikrogramov HA** na 0,5-mililitrski odmerek
10 pre-filled syringes without needle.
10 napolnjenih injekcijskih brizg brez igle.
Tell your doctor immediately if you experience any of the following side effects - you may need
Takoj povejte zdravniku, če opazite kateregakoli od naslednjih neželenih učinkov; morda boste
Non-clinical data reveal no special hazard for humans based on conventional repeat dose toxicity studies.
Predklinični podatki na osnovi običajnih študij toksičnosti pri ponavljajočih odmerkih ne kažejo posebnega tveganja za človeka.
None of the ingredients in the vaccine can
Nobena od sestavin cepiva ne more gripe povzročiti.
- Paraesthesia
- Parestezija
Not known (cannot be estimated from the available data)
Neznana (ni mogoče oceniti iz razpoložljivih podatkov)
Optaflu has minor influence on the ability to drive and use machines.
Cepivo Optaflu ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
No case of overdose has been reported for Optaflu.
Ni poročil o prevelikem odmerjanju cepiva Optaflu.
There is no human data on use of Optaflu during lactation.
Podatkov o uporabi cepiva Optaflu med dojenjem ni.
Optaflu is used to prevent flu in adults, especially in those who run an increased risk of experiencing associated complications in case they fall ill with flu.
Cepivo Optaflu se uporablja za preprečevanje gripe pri odraslih, zlasti tistih, ki so izpostavljeni povečanemu tveganju za zaplete, povezane z gripo.
Optaflu efficacy was defined as the prevention of culture-confirmed symptomatic influenza illness caused by viruses antigenically matched to those in the vaccine compared to placebo.
Učinkovitost cepiva Optaflu je bila opredeljena kot preprečitev (v primerjavi s placebom) laboratorijsko potrjene simptomatske gripe, ki jo povzročijo virusi, ki se ujemajo s cepilnimi sevi.
Not known (cannot be estimated from the available data):
Neznana (ni mogoče oceniti iz razpoložljivih podatkov):
Also, tell your doctor immediately if you experience any of the following side effects - you may need
Prav tako takoj povejte zdravniku, če opazite kateregakoli od naslednjih neželenih učinkov; morda
Multipack: 20 (2 packs of 10) pre-filled syringes (0.5 ml) without needle Multipack: 20 (2 packs of 10) pre-filled syringes (0.5 ml) with needle
Večkratno pakiranje: 20 (2 pakiranji po 10) napolnjenih injekcijskih brizg (0,5 ml) brez igle Večkratno pakiranje: 20 (2 pakiranji po 10) napolnjenih injekcijskih brizg (0,5 ml) z iglo
* produced in Madin Darby Canine Kidney (MDCK) cells (this is the special cell culture in which the influenza virus is grown) ** haemagglutinin
* razmnoženi v celicah pasjih ledvic Madin Darby (MDCK) (to je posebna celična kultura,
Animal data have not shown effects on female fertility.
Podatkov o učinkih na plodnost pri človeku ni.
Common (affects 1 to 10 users in 100):
Pogosti (pojavijo se pri 1 do 10 od 100 cepljenih):
Very rare (affects less than 1 user in 10,000):
Zelo redki (pojavijo se pri manj kot 1 od 10.000 cepljenih):
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Prefilled syringe
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH Napolnjena injekcijska brizga
4.5 Interaction with other medicinal products and other forms of interaction Optaflu may be given at the same time as other vaccines.
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
• injection site pain, reddening.
• bolečina na mestu injiciranja, rdečica.
The immunological response may be diminished if the patient is undergoing immunosuppressant
Če bolnik prejema imunosupresijsko zdravljenje, se lahko zmanjša imunološki odziv.
Rare (affects 1 to 10 users in 10,000):
Redki (pojavijo se pri 1 do 10 od 10.000 cepljenih):
The vaccine targets three strains of influenza virus following the recommendations by the World Health Organisation for the 2015/2016 season.
Cepivo je usmerjeno na tri seve virusa gripe z upoštevanjem priporočil Svetovne zdravstvene
• sweating, joint pain, chills, hardening or swelling at the site of the injection, bruising, fever,
• potenje, bolečina v sklepih, mrzlica, otrditve ali otekanje na mestu injiciranja, modrice, zvišana telesna temperatura, tresenje;
Pack sizes of 1, 10 or multipacks containing 20 (2 packs of 10) pre-filled syringes, each with or
Velikosti pakiranja po 1, 10 ali večkratna pakiranja po 20 (2 pakiranji po 10) napolnjenih injekcijskih brizg; z iglo ali brez nje.